Safinamide
CAS No. 133865-89-1
Safinamide( EMD-1195686 | FCE-26743 )
Catalog No. M11361 CAS No. 133865-89-1
A potent and selective inhibitor of MAO-B with IC50 of 98 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 35 | Get Quote |
|
| 10MG | 49 | Get Quote |
|
| 25MG | 83 | Get Quote |
|
| 50MG | 123 | Get Quote |
|
| 100MG | 177 | Get Quote |
|
| 500MG | 462 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSafinamide
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent and selective inhibitor of MAO-B with IC50 of 98 nM.
-
DescriptionA potent and selective inhibitor of MAO-B with IC50 of 98 nM; displays >5,000-fold selectivity over MAO-A; also inhibits glutamate release and dopamine reuptake, inhibits voltage-dependent Na+ and Ca2+ channels; is used for treatment ofParkinson's disease.Parkinson's Disease Approved.
-
In VitroSafinamide (1–300?μM) reduces the amplitude of the peak sodium currents in a concentration-dependent manner.?When currents are stimulated to a?Vtest?of +10 mV from a?Vh?of -110 mV, the IC50?value was 262?μM. When the holding potential is depolarized to -53 mV, the inhibitory effect of safinamide with a lower IC50?value (8?μM) in rat cortical neurons.
-
In VivoSafinamide (intraperitoneal?injection; 90 mg/kg; once daily; 14 days) treatment prior to MCAO significantly ameliorates MCAO-caused cerebral infarction volume, neurological deficit, disruption of the brain-blood barrier (BBB), and impairs expression of tight junction protein occludin and ZO-1 in mice.Safinamide (intraperitoneal?injection; 5 mg/kg, 15 mg/kg and 30 mg/kg) dose dependently inhibits the veratridine-induced GABA release and Glu release in vivo. At the dose 30 mg/kg, ?Safinamide prevents the effect of veratridine both on Glu (treatment?F1,8=1.31; time×treatment interaction?F8,64=2.4) and GABA (treatment?F1,8=4.04; time?F8,64=3.76, time×treatment interaction?F8,64?= 2.83) release.Safinamide causes a slight, albeit not significant, reduction of veratridine-stimulated Glu release at 0.5 mg/kg and full inhibition at 5 and 15 mg/kg in rat. Animal Model:Focal cerebral ischemia C57/BL6 male mouse ModelDosage:90 mg/kg Administration:Intraperitoneal?injection; once daily; 14 days Result:Significantly decreased infarction volume in brain areas.
-
SynonymsEMD-1195686 | FCE-26743
-
PathwayMetabolic Enzyme/Protease
-
TargetMAO
-
RecptorMAO
-
Research AreaNeurological Disease
-
IndicationParkinson Disease
Chemical Information
-
CAS Number133865-89-1
-
Formula Weight302.3434
-
Molecular FormulaC17H19FN2O2
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESCC(C(=O)N)NCC1=CC=C(C=C1)OCC2=CC(=CC=C2)F
-
Chemical NamePropanamide, 2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-, (2S)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Leonetti F, et al. J Med Chem. 2007 Oct 4;50(20):4909-16.
2. Strolin Benedetti MS, et al. J Pharm Pharmacol. 1994 Oct;46(10):814-9.
3. Caccia C, et al. Neurology. 2006 Oct 10;67(7 Suppl 2):S18-23.
molnova catalog
related products
-
Tetrindole mesylate
Tetrindole mesylate is a MAO-A inhibitor.
-
Femoxetine
Femoxetine is a 5-HT inhibitor with antidepressant activity that potentiates morphine-induced anti-injury feelings and inhibits MAO-A and MAO-B required for the production of high exercise capacity in mice.
-
N-(2-Aminoethyl)-5-c...
N-(2-Aminoethyl)-5-chlor-2-pyridincarbox is a reversible and selective mao-b inhibitor(Ki:7.9nM).
Cart
sales@molnova.com